• Molecular NameLevobupivacaine
  • SynonymNA
  • Weight288.435
  • Drugbank_IDDB01002
  • ACS_NO27262-47-1
  • Show 2D model
  • LogP (experiment)3.41
  • LogP (predicted, AB/LogP v2.0)3.09
  • pka8.09
  • LogD (pH=7, predicted)2.23
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-2.49
  • LogSw (predicted, AB/LogsW2.0)0.85
  • Sw (mg/ml) (predicted, ACD/Labs)0.2
  • No.of HBond Donors1
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds5
  • TPSA32.34
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA local anaesthetic drug belonging to the amino amide group.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding97.0
  • Volume of distribution (VD)66.9 L
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmLevobupivacaine is extensively metabolised (NADPH dependent) in the liver, by the cytochrome P450 system. The major metabolite is 3-hydroxylevobupivacaine which may be subsequently converted to glucuronic acid and sulfate ester conjugates.
  • Half life1.3 h
  • ExcretionApprox. 70% of a dose is excreted in urine as its metabolites and a little in faeces. No parent drug has been detected in urine or faeces. Approx. 95% of a dose is recovered within 48 h of dosing. Levobupivacaine crosses the placenta.
  • Urinary ExcretionN/A
  • Clerance39.1 L/h
  • ToxicityIntravenous administration of levobupivacaine can be associated with cardiac arrest.
  • LD50 (rat)N/A
  • LD50 (mouse)LD50=10 (iv)